Key Point: After 6 weeks of treatment in the STELLAR trial, a significantly greater percentage of patients treated with rosuvastatin 10 mg, 20 mg, and 40 mg achieved optimal LDL-C of <100 mg/dL than patients treated with the same doses of atorvastatin, simvastatin, and pravastatin (P<.002).

53% of patients taking rosuvastatin 10 mg achieved an LDL-C <100 mg/dL, while only 18% of  patients taking atorvastatin 10 mg were able to reduce their LDL-C to <100. Mean baseline LDL-C levels ranged from 187 mg/dL to 194 mg/dL

Rosuvastatin 40 mg was associated with the highest percentage of patients who achieved an LDL-C of <100 mg/dL

80% of patients treated with rosuvastatin 40 mg achieved <100 mg/dL

Reference

McKenney J, Jones PH, Adamczyk MA, et al for the STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial.Curr Med Res Opin. 2003;19:557-566.